The U.S. Food and Drug Administration on Thursday granted an early approval to Sarepta Therapeutics Inc's second treatment for Duchenne muscular dystrophy (DMD).
from Reuters: Company News https://ift.tt/2PgdxEB
via IFTTT
from Reuters: Company News https://ift.tt/2PgdxEB
via IFTTT
إرسال تعليق